Genomic characterization of breast cancer cells resistant to the histone deacetylase inhibitor romidepsin

被引：0
作者：
Ali-Rahmani, Fatima G. [1 ]
Robey, Robert [1 ]
Lack, Justin [1 ]
Tebase, Bethelihem [1 ]
Bates, Susan [2 ]
Gottesman, Michael [1 ]
机构：
[1] NCI, Bethesda, MD 20892 USA
[2] Columbia Univ, Ithaca, NY USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2018-LB-241
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LB-241
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax®)
    Harrison, Simon J.
    Bishton, Mark
    Bates, Susan E.
    Grant, Steven
    Piekarz, Richard L.
    Johnstone, Ricky W.
    Dai, Yun
    Lee, Becki
    Araujo, Maria E.
    Prince, H. Miles
    EPIGENOMICS, 2012, 4 (05) : 571 - 589
  • [32] Phase 2 Trial of the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Refractory Multiple Myeloma
    Niesvizky, Ruben
    Ely, Scott
    Mark, Tomer
    Aggarwal, Sangeeta
    Gabrilove, Janice L.
    Wright, John J.
    Chen-Kiang, Selina
    Sparano, Joseph A.
    CANCER, 2011, 117 (02) : 336 - 342
  • [33] Systematic assessment of potential cardiac effects of the novel histone deacetylase (HDAC) inhibitor romidepsin
    Cabell, C.
    Bates, S.
    Piekarz, R.
    Whittaker, S.
    Kim, Y.
    Godfrey, C.
    Schoonmaker, C.
    McCulloch, W.
    Nichols, J.
    Burris, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] The Histone Deacetylase Inhibitor Abexinostat Induces Cancer Stem Cells Differentiation in Breast Cancer with Low Xist Expression
    Salvador, Marion A.
    Wicinski, Julien
    Cabaud, Olivier
    Toiron, Yves
    Finetti, Pascal
    Josselin, Emmanuelle
    Lelievre, Helene
    Kraus-Berthier, Laurence
    Depil, Stephane
    Bertucci, Francois
    Collette, Yves
    Birnbaum, Daniel
    Charafe-Jauffret, Emmanuelle
    Ginestier, Christophe
    CLINICAL CANCER RESEARCH, 2013, 19 (23) : 6520 - 6531
  • [35] Histone Deacetylase Inhibitor LBH589 (Panobinostat) Suppresses the Activated-NFκB Pathway in Acquired Aromatase Inhibitor Resistant Breast Cancer Cells
    Kubo, M.
    Kanaya, N.
    Liu, Z.
    Chen, S.
    CANCER RESEARCH, 2011, 71
  • [36] Histone deacetylase inhibitors as differentiation agents in breast cancer cells
    Ismail, H.
    Bail, M.
    Laperriere, D.
    Mader, S.
    FEBS JOURNAL, 2014, 281 : 303 - 303
  • [37] Troglitazone inhibits histone deacetylase activity in breast cancer cells
    Davies, G. F.
    Ross, A. R.
    Arnason, T. G.
    Juurlink, B. H. J.
    Harkness, T. A. A.
    CANCER LETTERS, 2010, 288 (02) : 236 - 250
  • [38] Histone deacetylase inhibitors as differentiation agents in breast cancer cells
    Ismail, Houssam
    Bail, Martine
    LaperriSre, David
    Hilmi, Khalid
    Mader, Sylvie
    CANCER RESEARCH, 2013, 73
  • [39] Histone deacetylase inhibitor suberoylanilide hydroxamic acid targets breast cancer stem cells and inhibits metastasis
    Chu, K.
    Green, T. L.
    Boley, K. M.
    Cristofanilli, M.
    Robertson, F. M.
    CANCER RESEARCH, 2013, 73
  • [40] Characterization of inhibitor-resistant histone deacetylase activity in plant-pathogenic fungi
    Baidyaroy, D
    Brosch, G
    Graessle, S
    Trojer, P
    Walton, JD
    EUKARYOTIC CELL, 2002, 1 (04) : 538 - 547
12345